Abstract | INTRODUCTION: PATIENTS AND METHODS: RESULTS: The two populations were homogeneous at inclusion: the majority of the patients had a history of allergies, with a nonspecific disrupted allergy workup ( IgE and eosinophils) and a higher initial score for the children included in the study. The scores decreased sharply at D7 (50% reduction) and at D28 (bordering 1) with no significant difference between the two groups. Tolerance to the treatment judged by unusual sensations upon instillation was better for the NAAGA treatment (80.8% of the cases). Clinical and functional signs disappeared without recourse to corticoids. CONCLUSION: In the moderate forms of seasonal and intra-annual allergic conjunctivitis, NAAGA treatment alone is sufficient. The association with Levocabastine is necessary only in cases of highly bothersome functional signs. The use of corticoids should be reserved for the serious forms.
|
Authors | S Lazreg, J Colin, D Renault, D Hartani |
Journal | Journal francais d'ophtalmologie
(J Fr Ophtalmol)
Vol. 31
Issue 10
Pg. 961-7
(Dec 2008)
ISSN: 1773-0597 [Electronic] France |
Vernacular Title | Traitement de la conjonctivite allergique per-annuelle et saisonnière: comparaison de deux protocoles thérapeutiques. |
PMID | 19107071
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Allergic Agents
- Dipeptides
- Histamine H1 Antagonists, Non-Sedating
- Piperidines
- isospaglumic acid
- levocabastine
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-Allergic Agents
(therapeutic use)
- Child
- Child, Preschool
- Clinical Protocols
- Conjunctivitis, Allergic
(drug therapy)
- Dipeptides
(therapeutic use)
- Female
- Histamine H1 Antagonists, Non-Sedating
(therapeutic use)
- Humans
- Male
- Middle Aged
- Piperidines
(therapeutic use)
- Prospective Studies
- Seasons
- Young Adult
|